Glaukos begins phase 2 program for 3rd gen iLink therapy to treat thinning of cornea

Mar. 14, 2022 9:47 AM ETGlaukos Corporation (GKOS)By: Dania Nadeem, SA News Editor

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples

gorodenkoff/iStock via Getty Images

  • Glaukos (NYSE:GKOS) said it began a phase 2 program for its third generation iLink therapy to treat keratoconus, a type of eye disorder.
  • Keratoconus occurs when the cornea thins and gradually bulges outward into a cone shape, causing blurred vision.
  • The company's iLink platform consists of single-use drug formulations, which work by delivering ultraviolet light to the cornea to induce a reaction called corneal cross-linking, designed to strengthen and reshape the cornea.
  • The third-generation iLink therapy is a corneal cross-linking treatment designed to customize the therapeutic capabilities, and build upon Glaukos’ first-generation iLink therapy called iLink Epi-off and its second-generation iLink investigational treatment known as iLink Epi-on.
  • The phase 2 program consists of two separate trials and both will have follow-up period of 6 months.
  • The company expects to enroll patients across both trials at sites in the U.S., Europe, South America and Asia.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.